Immunotherapy player Altor BioScience just raised a $10.7 million equity round, according to a regulatory filing. Altor BioScience engineers a way to direct the immune system to treat a number of blood cancers, bladder cancer and acute respiratory disease.
It has three platforms: A soluble T-cell antigen receptor that zeroes in on cancerous or viral targets; a monoclonal antibody approach using tissue factor antagonists; and an IL-15 platform that’s meant to harness IL-15 super-agonists, antagonists and protein scaffolds to build novel immune molecules.
Calls and emails to the Florida company about this new round have yet to be returned. It looks from the SEC filings that this is the largest round Altor has raised to date.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Altor BioScience has been working on this approach for more than two decades, yet it remains venture-funded, with some revenue from creating reagents for research. It looks like Altor’s core science may finally be coming close to an inflection point, given the progress of several clinical programs:
This charts Altor’s progress by technology in the pipeline:
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
